Department for International Trade written question – answered at on 1 February 2022.
To ask the Secretary of State for International Trade, what steps the Government has taken in line with its support for voluntary licences to encourage (a) Pfizer and (b) Moderna to share their covid-19 vaccine technology with potential mRNA manufacturers across Africa, Latin America and Asia identified by MSF and Human Rights Watch; and if she will make a statement.
The role of the legal framework provided by the TRIPS Agreement has and will continue to provide innovators the confidence to invest in developing health products and technologies and to form collaborative partnerships. This is evidenced with over 300 successful voluntary licensing and technology transfer partnerships, which are contributing to the production of approximately 1.5 billion COVID-19 vaccine doses per month.
We encourage industry to continue forming voluntary licensing and technology transfer partnerships. Working with commercial partners within the existing international IP framework is the most effective way to make use of global capacity to produce life-saving medicines at pace.
Yes0 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.